Key facts
- It has raised $101.4M; the latest was Later Stage VC ($71.0M) in Jun 2024.
- Notable investors include Kinled Holding, Polaris Partners, EQT Life Sciences, Kurma Partners, EQT — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Vico Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vico Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vico Therapeutics
Developer of modulating therapies designed for patients suffering from severe neurological disorders. The company's initial focus is on spinocerebellar ataxia which is a subgroup of hereditary ataxia, a neurodegenerative disorder, and a neurodevelopmental disorder primarily affecting girls, enabling medical professionals to provide therapy for rare neurological disorders.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2019
- Employees
- 42
- Website
- vicotx.com/
- Ownership
- Privately Held (backing)
Vico Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vico Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vico Therapeutics in its N-PORT filings yet. We sweep new filings monthly.